Erlotinib (NSC 718781): Applied EGFR Pathway Inhibition in C
2026-07-24
Erlotinib (NSC 718781) empowers researchers to interrogate EGFR-driven oncogenic signaling with high precision, supporting robust cell proliferation and apoptosis assays. This article translates cutting-edge reference findings and technical insights into actionable protocols, troubleshooting strategies, and advanced applications for translational cancer research.
Catalpol Reverses Triptolide-Induced Liver Injury via SIRT1/
2026-07-23
This study demonstrates that catalpol protects against triptolide-induced hepatic glucose metabolic disorders and oxidative stress by activating SIRT1 and modulating HIF-1α acetylation. The mechanistic insight supports catalpol as a potential therapeutic for drug-induced hepatotoxicity.
NP-40 Lysis Buffer: Non-Denaturing Extraction for Neuroimmun
2026-07-23
APExBIO’s NP-40 Lysis Buffer empowers precise protein extraction from animal, plant, fungal, and bacterial cells, preserving native complexes for advanced immunological assays. Recent neuroinflammation research underlines its critical role in dissecting complex signaling networks, making it the buffer of choice for robust, reproducible results.
Toremifene Citrate: Advanced Workflows in Breast Cancer Rese
2026-07-22
Toremifene Citrate, a robust oral selective estrogen receptor modulator, enables reproducible manipulation of estrogen signaling for breast cancer and endocrinology research. This article details optimal in vitro and in vivo workflows, highlights insights from systematic evidence, and provides troubleshooting strategies to maximize scientific impact with APExBIO’s trusted compound.
Tioconazole in Antifungal Research: Protocols, Precision, an
2026-07-22
Explore Tioconazole as an advanced antifungal medication, delving into its precise mechanism, rigorous research protocols, and unique integration with metabolic-genomic studies. This article offers a fresh, protocol-driven perspective for scientists advancing antifungal drug development.
Alternariol: Mechanistic Insights for Mycotoxin Research
2026-07-21
Alternariol (AOH) is a mycotoxin with well-characterized antifungal, phytotoxic, and hepatotoxic properties. Recent omics-based studies elucidate its direct role in hepatic stellate cell activation through NF-κB, ferroptosis, and autophagy pathways. This article synthesizes evidence, parameters, and workflow implications for mycotoxin and cytochrome P450 research.
Selective β1 Blockade Preserves Hematopoietic Recovery Post-
2026-07-21
This study demonstrates that nonselective β-adrenergic receptor inhibitors, but not β1-selective agents, impair hematopoietic regeneration after hematopoietic cell transplantation (HCT) in mice and humans. The findings clarify the mechanistic role of β-adrenergic signaling in post-transplant recovery and guide clinical and experimental β-blocker selection.
Vancomycin: Strategic Tool for Translational Resistance Rese
2026-07-20
This thought-leadership article illuminates the critical role of Vancomycin—a high-purity glycopeptide antibiotic from APExBIO—in unraveling bacterial resistance mechanisms and supporting translational microbiome research. Integrating mechanistic insights and protocol guidance, it bridges foundational cell wall synthesis inhibition with advanced assay design, highlights current evidence, and strategically frames Vancomycin’s impact within contemporary microbiota-immunity research, including the pivotal interplay of microbial metabolites in disease models.
Synergistic Dual OXPHOS Blockade: LRPPRC Inhibition and Dasa
2026-07-20
This study identifies a robust synergy between LRPPRC inhibition and dasatinib treatment, providing a dual-genome strategy to disrupt oxidative phosphorylation (OXPHOS) in cancer cells. These findings highlight a pathway-specific rationale for combination therapies in LRPPRC-overexpressing tumors and inform experimental approaches in metabolic cancer research.
Energy Deficiency, ATG4B Nuclear Translocation, and DNA Repa
2026-07-19
This study uncovers a direct mechanistic link between cellular energy deficiency and impaired DNA repair in acute myeloid leukemia (AML). By demonstrating that nuclear translocation of ATG4B under energy stress disrupts PRMT1-mediated MRE11 methylation, the research highlights a metabolic vulnerability that drives genomic instability and leukemia progression.
Thiamet G: Transforming O-GlcNAcylation for Translational Re
2026-07-18
This thought-leadership article examines the strategic and mechanistic landscape of O-GlcNAcylation modulation in translational models, focusing on the role of Thiamet G—a potent, selective O-GlcNAcase inhibitor. Bridging cutting-edge mechanistic studies, including recent revelations on Wnt signaling and bone formation, with actionable guidance, this piece provides translational researchers with a roadmap for deploying Thiamet G from APExBIO in complex disease models and workflow optimization.
Radicicol: Precision Hsp90 Inhibitor for Immunity and Cell F
2026-07-17
Discover how Radicicol, a potent Hsp90 inhibitor, is redefining advanced research in immunity, cell differentiation, and apoptosis. This in-depth article explores unique mechanistic insights and practical assay guidance, grounded in the latest scientific findings.
NF 449: A Gsa-Selective Antagonist for Precision G Protein R
2026-07-17
The reference study identifies NF 449 as a highly selective antagonist of the Gsa protein, demonstrating its ability to uncouple β-adrenergic receptor/Gs tandems with minimal off-target effects on Gi/Go and Gq pathways. This discovery enables more precise investigation of G protein-mediated signaling, offering new avenues for dissecting receptor–effector specificity in cellular pharmacology.
Cy5.5 NHS Ester (Non-Sulfonated): Elevating In Vivo NIR Imag
2026-07-16
Explore how Cy5.5 NHS ester (non-sulfonated) transforms near-infrared fluorescence imaging for biomolecule labeling in advanced biological systems. This article offers a molecular-level analysis, filling critical gaps left by existing guides.
Camptothecin: Precision Topoisomerase I Inhibitor for DNA Da
2026-07-16
Camptothecin is a potent topoisomerase I inhibitor that induces DNA damage and autophagy, activating the ATM-Chk2-p53-p21 pathway in cancer models. This dossier delineates its mechanism, benchmarks, and optimal use for DNA damage research.
505 records 14/34 page Previous Next First page 上5页 1112131415 下5页 Last page